Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas.
We report the results of treatment with single agent 2'-deoxycoformycin (Pentostatin) in two patients with Hepatosplenic gammadelta T-cell lymphoma (HSgammadeltaTCL), a rare lymphoma subtype with a highly unfavorable prognosis. Present and previous data reviewed here demonstrates the striking cytotoxic activity of Pentostatin against gammadelta+ tumor T cells. Further studies are warranted to define the optimal strategy to fully exploit therapeutic potential of this drug in patients with HSgammadeltaTCL.
Corazzelli
Gaetano
G
Hematology-Oncology Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Via Mariano Semmola, I-80131, Naples, Italy.
Capobianco
Gaetana
G
Russo
Filippo
F
Frigeri
Ferdinando
F
Aldinucci
Donatella
D
Pinto
Antonio
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D015649:Pentostatin / Q000627:therapeutic use*; D016692:Receptors, Antigen, T-Cell, gamma-delta; D013160:Splenic Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D016692:Receptors, Antigen, T-Cell, gamma-delta; D015649:Pentostatin